Conversely, an in-vitro study on primary cells from RR-MM treated with lenalidomide revealed that the compound modestly decreased PD-L1 surface expression on malignant PCs, and more significantly on monocytes/macrophages and myeloid MDSCs. Here, CD274 is linked to Miyoshi myopathy.